JPWO2020254985A5 - - Google Patents

Download PDF

Info

Publication number
JPWO2020254985A5
JPWO2020254985A5 JP2021575482A JP2021575482A JPWO2020254985A5 JP WO2020254985 A5 JPWO2020254985 A5 JP WO2020254985A5 JP 2021575482 A JP2021575482 A JP 2021575482A JP 2021575482 A JP2021575482 A JP 2021575482A JP WO2020254985 A5 JPWO2020254985 A5 JP WO2020254985A5
Authority
JP
Japan
Prior art keywords
compound
pharmaceutically acceptable
administration
acceptable salt
agent
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2021575482A
Other languages
Japanese (ja)
Other versions
JP2022537047A (en
Publication date
Application filed filed Critical
Priority claimed from PCT/IB2020/055653 external-priority patent/WO2020254985A1/en
Publication of JP2022537047A publication Critical patent/JP2022537047A/en
Publication of JPWO2020254985A5 publication Critical patent/JPWO2020254985A5/ja
Pending legal-status Critical Current

Links

Claims (12)

化合物：
Figure 2020254985000001
 またはその薬学上許容可能な塩。 Compound:
Figure 2020254985000001
 or a pharmaceutically acceptable salt thereof. 以下に示す立体化学を有する請求項１に記載の化合物
Figure 2020254985000002
 またはその薬学上許容可能な塩。 A compound according to claim 1 having the stereochemistry shown below.
Figure 2020254985000002
 or a pharmaceutically acceptable salt thereof. 以下に示す立体化学を有する請求項２に記載の化合物
Figure 2020254985000003
 またはその薬学上許容可能な塩。 A compound according to claim 2 having the stereochemistry shown below.
Figure 2020254985000003
 or a pharmaceutically acceptable salt thereof. 請求項１～３のいずれか一項に記載の化合物または塩を含んでなる、医薬組成物。 A pharmaceutical composition comprising a compound or salt according to any one of claims 1-3. 薬学上許容可能な賦形剤をさらに含んでなる、請求項４に記載の組成物。 5. The composition of Claim 4, further comprising a pharmaceutically acceptable excipient. 経口投与、筋肉内注射、または皮下注射に好適である、請求項４または請求項５に記載の組成物。 6. A composition according to claim 4 or 5, suitable for oral administration, intramuscular injection or subcutaneous injection. 請求項１～３のいずれか一項に記載の化合物または塩の投与を含んでなる、ヒトにおけるＨＩＶ感染症を治療する方法。 A method of treating HIV infection in humans comprising administration of a compound or salt according to any one of claims 1-3. 前記投与が経口である、請求項７に記載の方法。 8. The method of claim 7, wherein said administration is oral. 前記投与が、筋肉内注射または皮下注射である、請求項７に記載の方法。 8. The method of claim 7, wherein said administration is intramuscular injection or subcutaneous injection. 前記方法が、ヒトにおけるＨＩＶ感染症の治療に使用される少なくとも１つの他の剤の投与をさらに含んでなる、請求項７に記載の方法。 8. The method of claim 7, wherein said method further comprises administering at least one other agent used to treat HIV infection in humans. 少なくとも１つの他の剤が、アバカビル、アタザナビル、ビクテグラビル、カボテグラビル、ドルテグラビル、ダルナビル、ドラビリン、フォステムサビル、ラミブジン、マラビロク、リルピビリン(rilpiverine)、テノホビルジソプロキシル、テノホビル、テノホビルアラフェナミド(afenamide)、Ｓ－６４８４１４、ＧＳＫ３６４０２５４、抗体Ｎ６ＬＳ、およびＧＳＫ３７３９９３７／ＶＨ３７３９９３７からなる群から選択される、請求項１０に記載の方法。 at least one other agent is abacavir, atazanavir, bictegravir, cabotegravir, dolutegravir, darunavir, doravirine, fostemsavir, lamivudine, maraviroc, rilpiverine, tenofovir disoproxil, tenofovir, tenofovir alafenamide, 11. The method of claim 10, selected from the group consisting of S-648414, GSK3640254, antibody N6LS, and GSK3739937/VH3739937. 少なくとも１つの他の剤が、ドルテグラビル、ラミブジン、フォステムサビル、カボテグラビル、抗体Ｎ６ＬＳ、およびＧＳＫ３７３９９３７／ＶＨ３７３９９３７からなる群から選択される、請求項１１に記載の方法。 12. The method of claim 11, wherein the at least one other agent is selected from the group consisting of dolutegravir, lamivudine, fostemsavir, cabotegravir, antibody N6LS, and GSK3739937/VH3739937.
JP2021575482A 2019-06-19 2020-06-17 Pyrido[2,3-D]pyrimidine derivatives as inhibitors of human immunodeficiency virus replication Pending JP2022537047A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962863406P 2019-06-19 2019-06-19
US62/863,406 2019-06-19
PCT/IB2020/055653 WO2020254985A1 (en) 2019-06-19 2020-06-17 Pyrido[2,3-d]pyrimidine derivatives as inhibitors of human immunodeficiency virus replication

Publications (2)

Publication Number Publication Date
JP2022537047A JP2022537047A (en) 2022-08-23
JPWO2020254985A5 true JPWO2020254985A5 (en) 2023-06-21

Family

ID=71738195

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021575482A Pending JP2022537047A (en) 2019-06-19 2020-06-17 Pyrido[2,3-D]pyrimidine derivatives as inhibitors of human immunodeficiency virus replication

Country Status (29)

Country Link
US (1) US12129255B2 (en)
EP (1) EP3986561B1 (en)
JP (1) JP2022537047A (en)
KR (1) KR20220024608A (en)
CN (1) CN114245795B (en)
AR (1) AR119174A1 (en)
AU (1) AU2020295793B2 (en)
BR (1) BR112021025655A2 (en)
CA (1) CA3143136A1 (en)
CL (1) CL2021003388A1 (en)
CO (1) CO2021017479A2 (en)
CR (1) CR20210664A (en)
DK (1) DK3986561T3 (en)
ES (1) ES2974541T3 (en)
FI (1) FI3986561T3 (en)
HR (1) HRP20240501T1 (en)
HU (1) HUE065762T2 (en)
IL (1) IL288750A (en)
LT (1) LT3986561T (en)
MA (1) MA56526B1 (en)
MD (1) MD3986561T2 (en)
MX (1) MX2021016149A (en)
PE (1) PE20220510A1 (en)
PL (1) PL3986561T3 (en)
PT (1) PT3986561T (en)
RS (1) RS65304B1 (en)
SI (1) SI3986561T1 (en)
UY (1) UY38755A (en)
WO (1) WO2020254985A1 (en)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11541055B2 (en) 2018-10-24 2023-01-03 VIIV Healthcare UK (No.5) Limited Inhibitors of human immunodeficiency virus replication
AR119174A1 (en) 2019-06-19 2021-12-01 Viiv Healthcare Uk No 5 Ltd HUMAN IMMUNODEFICIENCY VIRUS REPLICATION INHIBITORS
BR112022010574A2 (en) * 2019-12-09 2022-08-23 Viiv Healthcare Co PHARMACEUTICAL COMPOSITIONS INCLUDING CABOTEGRAVIR
IL296182A (en) * 2020-03-06 2022-11-01 Viiv Healthcare Uk No 5 Ltd Inhibitors of human immunodeficiency virus replication
JP2023521460A (en) * 2020-04-15 2023-05-24 ビーブ、ヘルスケア、ユーケー、（ナンバー５）、リミテッド Inhibitors of human immunodeficiency virus replication
EP4415685A1 (en) 2021-10-13 2024-08-21 ViiV Healthcare UK (No.5) Limited Inhibitors of human immunodeficiency virus replication

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI0206636B8 (en) 2001-02-02 2021-05-25 Bristol Myers Squibb Co antiviral composition and activity of substituted azaindoloxoacetic piperazine derivatives, pharmaceutical compositions containing them and uses
US20030207910A1 (en) 2001-02-02 2003-11-06 Tao Wang Composition and antiviral activity of substituted azaindoleoxoacetic piperazine derivatives
AU2009266421B2 (en) * 2008-07-02 2013-07-11 Avexa Limited Compounds having antiviral properties
CN102464654B (en) 2010-11-12 2016-01-13 上海泓博智源医药技术有限公司 Antiviral compound
ES2553449T3 (en) 2011-07-06 2015-12-09 Gilead Sciences, Inc. Compounds for HIV treatment
CN102863512B (en) 2011-07-07 2016-04-20 上海泓博智源医药技术有限公司 Antiviral compound
EP2943493B1 (en) 2013-01-09 2017-08-02 Gilead Sciences, Inc. Therapeutic compounds for the treatment of viral infections
TW201443037A (en) 2013-01-09 2014-11-16 Gilead Sciences Inc Therapeutic compounds
CA2896244C (en) 2013-01-09 2017-07-04 Gilead Sciences, Inc. 5-membered heteroaryls and their use as antiviral agents
TWI694071B (en) 2013-03-01 2020-05-21 美商基利科學股份有限公司 Therapeutic compounds for treating a retroviridae viral infection
WO2015130966A1 (en) 2014-02-28 2015-09-03 Gilead Sciences, Inc. Antiviral agents
US10202353B2 (en) 2014-02-28 2019-02-12 Gilead Sciences, Inc. Therapeutic compounds
CA2958742C (en) 2014-08-29 2019-04-30 Gilead Sciences, Inc. Antiretroviral agents
CA3021227C (en) 2016-08-19 2020-11-03 Gilead Sciences, Inc. Therapeutic compounds useful for the prophylactic or therapeutic treatment of an hiv virus infection
ES2826748T3 (en) * 2016-09-02 2021-05-19 Gilead Sciences Inc Derivatives of 4,6-diamino-pyrido [3,2-d] pyrimidine as modulators of Toll-like receptors
UY37710A (en) 2017-05-02 2018-11-30 Viiv Healthcare Uk No 5 Ltd INHIBITORS OF THE HUMAN IMMUNODEFICIENCY VIRUS REPLICATION
UY38559A (en) * 2019-02-01 2020-07-31 Viiv Healthcare Uk No 5 Ltd HUMAN IMMUNODEFICIENCY VIRUS REPLICATION INHIBITORS
AR119174A1 (en) 2019-06-19 2021-12-01 Viiv Healthcare Uk No 5 Ltd HUMAN IMMUNODEFICIENCY VIRUS REPLICATION INHIBITORS

Similar Documents

Publication Publication Date Title
JP7330312B2 (en) Modulators of Toll-like receptors for treating HIV
JP2022191257A5 (en)
CN112423750A (en) Capsid inhibitors for the treatment of HIV
HRP20240501T1 (en) Pyrido[2,3-d]pyrimidine derivatives as inhibitors of human immunodeficiency virus replication
RU2329050C2 (en) Combination of cytochrome-p450-dependent protease inhibitors
EP3356355B1 (en) Compounds and combinations for the treatment of hiv
RU2002111657A (en) HEXAHYDROFURO [2,3-b] FURAN-3-IL-N- {3 - [(1,3-BENZODIOXOL-5-ILSULFONIL) (Isobutyl) AMINO] -1-BENZYL-2-HYDROXYPROPYL} CARBAMRUS KARINOBI
RU2018132408A (en) PHARMACEUTICAL COMPOSITIONS CONTAINING ANTIRETROVIRAL MEDICINES AND IMPROVERS OF PHARMACOKINETICS
JPWO2020254985A5 (en)
JP2005507944A5 (en)
AU2019344929B2 (en) Integrase inhibitors for the prevention of HIV
JPWO2020222108A5 (en)
JP2002533470A5 (en)
RU99119233A (en) PHARMACEUTICAL COMPOSITIONS containing ibuprofen and domperidone for the treatment of migraine
US11191763B2 (en) HIV post-exposure prophylaxis
RU2022101023A (en) HUMAN IMMUNODEFICIENCY VIRUS REPLICATION INHIBITORS
JP2020536098A5 (en)
JPWO2020123449A5 (en)
JPWO2020157692A5 (en)
US20100022575A1 (en) Oxymatrine compositions and related methods for treating and preventing chronic infectious diseases
WO2020139163A3 (en) Combination of antiviral agents
RU2016148641A (en) Isopropyl N - [{[(1R) -2- (6-amino-9H-purin-9-yl) -1-methylethoxy] methyl} (1,3-benzothiazol-6-yl-hydroxy) phosphoryl] -L- alaninate fumarate as an antiviral drug - Tenofovir prodrugs
US20220265689A1 (en) Hiv pre-exposure prophylaxis
RU2021102899A (en) COMPOUNDS SUITABLE FOR HIV THERAPY
RU2024112404A (en) INHIBITORS OF HUMAN IMMUNODEFICIENCY VIRUS REPLICATION